## STE: STERIS plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.7% below STRENGTH zone (4.0-10.0%); PEG 1.75 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($253.32)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Should You Hold STERIS Stock in Your Portfolio for Now?**
- Source: TradingView | 20251204T130854 | Neutral | Relevance: 100%
- STERIS plc (STE) is experiencing growth driven by its service revenues in Applied Sterilization Technologies (AST) and increased adoption in its Healthcare segment, with shares outperforming the industry and S&P 500. However, macroeconomic volatility and adverse currency fluctuations pose concerns for the company. Despite these challenges, positive investments in innovation and strong quarterly results suggest potential for continued growth.

**2. STERIS plc $STE Shares Sold by Mackenzie Financial Corp**
- Source: MarketBeat | 20251205T114508 | Somewhat-Bullish | Relevance: 100%
- Mackenzie Financial Corp sold 6,748 shares of STERIS plc, reducing its stake by 36.4%. Despite this sale, institutional ownership remains high at 94.69% with other large institutions increasing their positions. STERIS recently beat quarterly earnings estimates, provided strong FY2026 guidance, and declared a quarterly dividend.

**3. Arrowstreet Capital Limited Partnership Grows Position in STERIS plc $STE**
- Source: MarketBeat | 20251205T085014 | Somewhat-Bullish | Relevance: 100%
- Arrowstreet Capital Limited Partnership significantly increased its holdings in STERIS plc (NYSE:STE) by 666.7% in the second quarter, now owning 221,039 shares worth $53 million. Other institutional investors also adjusted their stakes in the medical equipment provider. STERIS has shown a 0.6% increase in trading, with strong financial metrics, a recent dividend announcement, and a "Moderate Buy" consensus rating from analysts.

**4. Should You Hold STERIS Stock in Your Portfolio for Now?**
- Source: The Globe and Mail | 20251204T150817 | Neutral | Relevance: 100%
- STERIS plc (STE) is exhibiting strong growth in its Applied Sterilization Technologies (AST) and Healthcare segments, driven by successful market adoption and increasing service revenues. Despite these positives, macroeconomic volatilities and adverse currency fluctuations pose concerns for the stock. The company has a Zacks Rank #3 (Hold) and has outperformed its industry and the S&P 500 over the past year.

**5. STERIS plc $STE Shares Purchased by Locust Wood Capital Advisers LLC**
- Source: MarketBeat | 20251204T130932 | Bullish | Relevance: 100%
- Locust Wood Capital Advisers LLC increased its holding in STERIS plc (NYSE:STE) by 12.4% during Q2, bringing its total to 416,588 shares, valued at approximately $100.1 million. STERIS reported strong Q-earnings, beating EPS and revenue expectations, and provided optimistic FY2026 guidance. The company also announced a quarterly dividend of $0.63 per share, while several insiders sold shares totaling approximately $6.62 million in the last three months.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.3% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.75 elevated, pricing in significant growth expectations. Forward P/E 23.6x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.2B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.75 |
| Forward P/E | 23.6 |
| Current P/E | 25.8 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.6% to -1.7% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.7pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.68), momentum weakening. RSI neutral at 59. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.72% (CS: 40) | Neutral |
| RSI_14 | 59.4 | Neutral |
| MACD Histogram | -0.68 | Bearish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 1.055x | Above |
| vs SMA200 | 1.107x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $263.28
- **Stop Loss:** $253.32 (3.8% risk)
- **Target:** $273.24 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 50
- **Position Value:** $13,164.00
- **Portfolio %:** 13.16%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*